Atomoxetine Discontinuation Before Methylphenidate ER Switching
Atomoxetine does not require tapering solely to prevent a drug-discontinuation or withdrawal syndrome. [1] Atomoxetine has been discontinued abruptly without evidence of symptom rebound or discontinuation-emergent adverse effects in clinical trial settings. [2] Cross-tapering or short-term overlap with methylphenidate is commonly used during switching, but tapering atomoxetine is not a prerequisite. [3]
Medication Discontinuation Approach
- Abrupt discontinuation of atomoxetine is acceptable when switching to another ADHD medication because rebound and withdrawal syndromes were not observed in available evidence. [1] [2]
- Temporary overlap or cross-tapering is an option during conversion to methylphenidate when tolerability and symptom coverage are priorities. [3]
Medication Selection Algorithm During Switching
Switching strategies described in the ADHD literature include: [3]
- Gap switching (stop atomoxetine and start methylphenidate on a new day). [3]
- Cross-tapering/overlap (atomoxetine continues for part of the initiation period of methylphenidate). [3]
Key Evidence Supporting No Required Taper
- The STRATTERA (atomoxetine) prescribing information reports no evidence of symptom rebound or adverse reactions suggesting a drug-discontinuation or withdrawal syndrome with discontinuation in studied settings. [1]
- A prospective, placebo-controlled assessment found no statistically significant differences in discontinuation-emergent adverse events between patients abruptly discontinuing atomoxetine versus continuing placebo, supporting the absence of a discontinuation syndrome signal. [2]
Monotherapy vs Combination During Transition
- Atomoxetine may be co-administered with methylphenidate during the switching period without undue concern for cardiovascular adverse events in the cited review, with monitoring still required. [3]
- Routine long-term combination therapy is not the goal; overlap is typically limited to the transition period. [3]
Initiation Thresholds and Monitoring
- Cardiovascular monitoring of blood pressure and heart rate should accompany stimulant initiation during any overlap or transition strategy. [3]
Common Pitfalls to Avoid
- Avoid treating atomoxetine tapering as mandatory based on concern for withdrawal syndromes, since atomoxetine discontinuation has not shown a discontinuation-withdrawal pattern comparable to some antidepressants. [1] [2]
- Avoid inadequate monitoring of blood pressure and heart rate during stimulant initiation and overlap periods. [3]
Targets or Goals of Therapy During the Switch
- The transition goal is achievement of effective ADHD symptom control on the new regimen while minimizing adverse effects during the initiation window. [3]